search

Active clinical trials for "Lymphoma, Extranodal NK-T-Cell"

Results 131-140 of 154

MESA Treatment for NK/T Cell Lymphoma

LymphomaExtranodal NK-T-Cell

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma

Unknown status18 enrollment criteria

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

LymphomaExtranodal NK-T-Cell

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

Unknown status8 enrollment criteria

Tofacitinib Combined With Chidamide in R/R ENKTCL

Extranodal NK/T-cell Lymphoma

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

Unknown status7 enrollment criteria

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Unknown status38 enrollment criteria

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Acute Myeloid LeukemiaPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma9 more

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

Unknown status19 enrollment criteria

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma...

Nasal Type Extranodal NK/T-Cell Lymphoma

This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma.

Unknown status20 enrollment criteria

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Extranodal NK-T-Cell LymphomaNasal and Nasal-Type

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

Unknown status11 enrollment criteria

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma...

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma15 more

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Unknown status60 enrollment criteria

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.

Unknown status16 enrollment criteria

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics,...

LymphomaExtranodal NK-T-Cell1 more

To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration. To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.

Unknown status28 enrollment criteria
1...13141516

Need Help? Contact our team!


We'll reach out to this number within 24 hrs